The Importance of Complete Response in Outcomes in Myeloma
暂无分享,去创建一个
[1] S. Lonial,et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma , 2010, Cancer.
[2] Michael L. Wang,et al. CR represents an early index of potential long survival in multiple myeloma , 2010, Bone Marrow Transplantation.
[3] B. Pégourié,et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Lonial. Risky business in myeloma. , 2009, Blood.
[5] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Reynolds,et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Greil,et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. , 2009, Blood.
[8] J. H. Lee,et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] M Boccadoro,et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders , 2009, Leukemia.
[10] A. Palumbo,et al. A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Escoda,et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Michael L. Wang,et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. , 2008, Blood.
[13] D. Esseltine,et al. Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study , 2008 .
[14] M. Kersten,et al. First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) , 2008 .
[15] P. Sonneveld,et al. Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study , 2008 .
[16] M. Baccarani,et al. Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma , 2008 .
[17] A. Órfão,et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.
[18] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[19] B. Barlogie,et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma , 2008, Cancer.
[20] M. Williams,et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi , 2008 .
[21] P. Moreau,et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial , 2008 .
[22] W. Jędrzejczak,et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Lonial,et al. Eliminating the complete response penalty from myeloma response assessment. , 2008, Blood.
[24] Marina Ruggeri,et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.
[25] H. Goldschmidt,et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma , 2008, Haematologica.
[26] F. Zhan,et al. Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling , 2007, Clinical Cancer Research.
[27] D. Dingli,et al. Improving Survival in Multiple Myeloma: Impact of Novel Therapies. , 2007 .
[28] P. Fayers,et al. Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial. , 2007 .
[29] D. Dingli,et al. Relationship between depth of response and outcome in multiple myeloma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Pégourié,et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.
[31] H. van de Velde,et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma , 2007, Haematologica.
[32] P. Sonneveld,et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. , 2007, Haematologica.
[33] M. Baccarani,et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P. Moreau,et al. The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials. , 2006 .
[35] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[36] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[37] M. Oken,et al. Complete response in multiple myeloma , 2006, Cancer.
[38] I. Lampert,et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients , 2006, Bone Marrow Transplantation.
[39] Vincenzo Callea,et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.
[40] John Crowley,et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.
[41] Jason McCoy,et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] P. Ravaud,et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. S. San Miguel,et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. , 2005, Blood.
[44] G. Morgan,et al. Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments , 2005, British journal of haematology.
[45] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[46] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[47] C. Crawley,et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients , 2003, Bone Marrow Transplantation.
[48] R. Champlin,et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma , 2001, Bone Marrow Transplantation.
[49] G. Morgan,et al. The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma , 2001, British journal of haematology.
[50] B. Barlogie,et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. , 2000, Blood.
[51] J. San-Miguel,et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients , 2000, British journal of haematology.
[52] M. Boccadoro,et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. , 1999, Blood.
[53] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[54] B. Barlogie,et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.
[55] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[56] P. Ljungman,et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. , 1994, Leukemia & lymphoma.
[57] Y. Saito,et al. [Combination chemotherapy of multiple myeloma]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.
[58] H. Wilson,et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.
[59] U. Mellqvist,et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. , 2006, Haematologica.
[60] T. Barbui,et al. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. , 2005, Haematologica.
[61] H. Johnsen,et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. , 2000, Blood.
[62] G. Martinelli,et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. , 2000, Haematologica.
[63] A. Palumbo,et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] M. Vignetti,et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. , 1999, Haematologica.
[65] B. Barlogie,et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.
[66] J. Rossi,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.